AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06219915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1
Description: Participants will take one 25mg placebo tablet 3 times a day for 10 days.
Study NCT06219915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2
Description: Participants will take one 100mg placebo tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.
Study NCT05227495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR cognitive training
Description: All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~They will receive one immersive leisure-based VR cognitive training for 40 minutes. VR cognitive training receives four gardening activities.~The cognitive elements including attention, working memory, processing speed, and executive function incorporated training.
Study NCT05227495 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional cognitive training
Description: All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~The control group is performing traditional cognitive training program.
Study NCT06184230 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Hepatitis A Vaccine
Description: Hepatitis A Vaccine
Study NCT06300567 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: collection of data of generated by real world follow up
Study NCT05651841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Tezepelumab is supplied as a sterile, single-use, preservation-free, clear, colourless to slightly yellow liquid for subcutaneous administration in accessorized pre-filled syringes (APFS).~Injections will be performed by study staff (doctors or nurses) during face-to-face study visits in participating centres.~Subcutaneous injections are performed in a different body-part following the suggested rotation diagram.
Study NCT06354010 — intervention group
Intervention type: GENETIC
Intervention: Genotyping
Description: Genotyping to determine if patients present mutations to the gene GJB2.
Study NCT06354010 — intervention group
Intervention type: OTHER
Intervention: Audiological assessments
Description: Audiological assessments
Study NCT05651841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: APFS containing analogous placebo identical in appearance:~Injections will be performed by study staff (doctors or nurses) during face-to-face study visits in participating centres.~Subcutaneous injections are performed in a different body-part following the suggested rotation diagram.
Study NCT05799703 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electrical stimulation device
Description: the device has 2 channels ,4 electrodes with multiple ems programs
Study NCT05799703 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesio taping
Description: kinesio tape a therapeutic tape that's applied strategically to the body to provide support, lessen pain, reduce swelling, and improve performance
Study NCT05519111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Dronabinol, an FDA approval oral agent containing synthetic tetrahydrocannabinol (THC)
Study NCT05519111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo equivalent
Study NCT05679583 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative Stereotactic body radiation therapy (SBRT), Pancreatic resection, Adjuvant Chemotherapy
Description: 1. Preoperative Stereotactic body radiation therapy (SBRT) For the gross pancreatic cancer lesion, 30 Gy/5 fx will be prescribed considering respiratory movement. And 20 Gy/5 fx will be prescribed to the triangle operation area including the common hepatic artery, celiac artery, and portal vein.~2. Pancreatic resection Surgical resection will be performed 2-4 weeks after the end of radiation therapy. The surgical method and resection range depend on the surgeon's judgment at the time of surgery.~3. Adjuvant Chemotherapy Adjuvant chemotherapy will be given under the judgment of the oncologist from 4 weeks after surgical resection, considering the pathological findings (R0 or R1 resection status, etc.) and the patient's medical condition. Adjuvant chemotherapy includes gemcitabine alone, gemcitabine plus capecitabine combination therapy, and mFOLFIRINOX.
Study NCT06378060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified transplantation system
Description: Conditioning regimen: fludarabine 30mg/m2×5\~6d,cyclophosphamide 50mg/kg×2d, melphalan 100mg/m2×1d aGVHD prophylaxis: PTCY 25mg/kg×2d, ATG 4.5mg/kg total, MMF 15mg/kg +5d\~+35d, Ruxolitinib 5mg bid -1d\~+50d and 2.5mg bid +51d\~+110d, CSA
Study NCT05710796 — intervention group
Intervention type: BEHAVIORAL
Intervention: Difference in gender, response to disease, diagnostic test values
Description: Gender difference: Prevalence of disease in male vs female Response to disease: Which group is more prone to cardiac involvement Diagnostic tests: Diagnostic confirmation of disease
Study NCT05947383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin 25 mg oral capsule
Study NCT05947383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Niacin 100 mg oral capsule
Study NCT06385600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Description: Group L will recieve labetalol intravenous infusion (Trandate, Gsk) in a concentration of 10 mg/ ml, thus 50 mg/ml equals to 5 ml/hr. The starting infusion rate of the antihypertensive medication is 5 ml/hr for an 80 Kg patient.
Study NCT06385600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentolamine
Description: Group P will receive phentolamine intravenous infusion (Rogitamine) in a concentration of 10 mg/ml, thus 1 µg/Kg/min equals to 4.8 ml/hr for an 80 Kg patient.
Study NCT04788212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Behavioral Activation Therapy for Autism Spectrum Disorder
Description: This will be a modification of the Group Behavioral Activation Therapy program (Chu et al., 2009) for treatment of depression, anxiety and/or anger in autistic adults.
Study NCT04721158 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous glucose monitor
Description: Eligible patients will have a Dexcom G6 Continuous Glucose Monitor placed for 10 days.
Study NCT06183736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL237 tablets
Description: CVL237 tablets, 200 mg, taken with food once daily for 28 consecutive days as a treatment cycle.
Study NCT05653401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate and diclofenac
Description: Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution Intravenous injection of 1 g of Magnesium Sulfate solution diluted in 10 ml of saline solution administered over 2 to 4 minutes
Study NCT05653401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocain and diclofenac
Description: Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution Intravenous injection of 10 ml of Lidocaine 1% solution administered over 2 to 4 minutes.
Study NCT05653401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo and diclofenac
Description: Intramuscular injection of 75 mg of Diclofenac solution and 10 ml Intravenous injection of serum saline ( as a Placebo Comparator ) administered over 2 to 4 minutes.
Study NCT06240520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat 20 MG Oral Capsule
Description: Panobinostat 20mg will be administered once orally
Study NCT06240520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrimethamine 200mg Oral Tablet
Description: Pyrimethamine 200mg will be administered once orally
Study NCT06240520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 MG Oral Capsule
Description: Lenalidomide 25mg will be administered once orally
Study NCT04980625 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg.
Study NCT04980625 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg.
Study NCT04644198 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Convalescent Plasma Infusion
Description: 250 mls of convalescent plasma on day 1 \& 2.
Study NCT06491225 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTE001 injection
Description: GTE-001 injection to treat Advanced lung adenocarcinoma
Study NCT04957680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CCBT
Description: computer-based treatment program for depressed adolescents
Study NCT04957680 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CCBT
Description: computer-based treatment program for depressed adolescents
Study NCT04880772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: exercise \& multivitamin (nutritional/dietary advice)
Study NCT05489744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]Afuresertib
Description: Suspension containing approximately 125 mg of Afuresertib (containing 150 µCi of \[14C\]Afuresertib) is administered orally on an empty stomach, with approximately 240 mL of water for suspending and drug taking.
Study NCT05312684 — intervention group
Intervention type: PROCEDURE
Intervention: cardiac surgery
Description: cardiovascular surgery including valve repair/replacement or CABG or combined procedures
Study NCT05096546 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be applied for the observational study.
Study NCT06511544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: rTMS delivered at 1 Hz for 1800 pulses over 30 minutes for 20 daily sessions, 5 days/week. Treatment will be directed to the ventromedial prefrontal cortex using each participant's structural MRI.
Study NCT06513390 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Exoskeleton of default mode
Description: Default mode: A standard control system offering a conventional assistive function of Exo-H3.
Study NCT06513390 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exoskeleton of default mode
Description: Default mode: A standard control system offering a conventional assistive function of Exo-H3.
Study NCT06513390 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Exoskeleton of Intelligent mode
Description: Intelligent mode: The adaptive CPG-based control system developed by our researchers from Exo-H3.
Study NCT06513390 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exoskeleton of Intelligent mode
Description: Intelligent mode: The adaptive CPG-based control system developed by our researchers from Exo-H3.
Study NCT04565912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sage extract mouthwash
Description: Patients will be exposed to sage extract mouthwash and will be instructed to use 10 ml of sage extract mouthwash 2 times per day for 1 minute, such a regimen will be continued for one month.
Study NCT04565912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorohexidine based mouthwash
Description: Patients will be exposed to Chlorohexidine based mouthwash , and will be instructed to use 10 ml of 0.12% chlorohexidine based mouthwash 2 times per day for 1 minute, such a regimen will be continued for one month
Study NCT04803175 — intervention group
Intervention type: DRUG
Intervention: Sacubitril-Valsartan
Description: Participants will receive individualized dosage and titration as part of routine medical care, and a the effect will be studied for at least 12 months. The investigator does not assign specific interventions to the study participants.
Study NCT04803175 — intervention group
Intervention type: DRUG
Intervention: Valsartan
Description: Participants will receive individualized dosage and titration as part of routine medical care, and a the effect will be studied for at least 12 months. The investigator does not assign specific interventions to the study participants.
Study NCT05079347 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV rapid test
Description: Using a rapid test to assess a patient's HIV status
Study NCT05096637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PreventiPlaque App
Description: PreventiPlaque is an app that supports patients with atherosclerotic plaque by strengthening their adherence.
Study NCT06207552 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BBM-F101 injection
Description: The dose of BBM-F101 injection will be calculated according to the participant's weight with single intravenous infusion.
Study NCT05765058 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group A
Description: Application of SDF (silver diamine fluoride) solution on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
Study NCT05765058 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group B
Description: Application of Sodium Fluoride varnish on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
Study NCT05765058 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group C
Description: Application of Placebo varnish (water-based) solution on the root caries lesions twice yearly in a professional setting. Application of Biosmalto tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
Study NCT05765058 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Group D
Description: Application of Placebo varnish (water-based) solution on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
Study NCT05481983 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Walk exercise
Description: The control group will be recommended to walk 5 days a week, 30-45 minutes (min.) (at least 150 minutes of physical activity per week), as recommended by ACOG for pregnant women. Exercise intensity will be given as 4-6 units for moderate-intensity exercise according to the Modified Perceived Difficulty Level (RPE).
Study NCT05481983 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One-on-one clinical exercise training
Description: One-on-one clinical exercise training will be given by a specialist physiotherapist who has received special training in antenatal exercise. The program is designed to be 2 days a week for 8 weeks.
Study NCT04430257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV and PrEP education
Description: Navigators will deliver Social Cognitive Theory-informed HIV and PrEP education.
Study NCT04430257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: Bachelors-level PrEP Navigators who are trained in motivational interviewing (MI) will use MI to promote the behavioral intervention.
Study NCT04430257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-solving and planning
Description: Bachelors-level PrEP Navigators will assist participants with problem-solving and planning.
Study NCT04430257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient navigation
Description: Ongoing PrEP navigation support to promote participants' initial and continued engagement with PrEP clinics affiliated with the two study sites
Study NCT04430257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP information
Description: A brief video that describes what PrEP is and how it works to prevent HIV via sexual and injection transmission will be shown to participants.
Study NCT04430257 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PrEP information
Description: A brief video that describes what PrEP is and how it works to prevent HIV via sexual and injection transmission will be shown to participants.
Study NCT04430257 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referrals
Description: Study staff will provide basic information about PrEP and referrals to PrEP clinicians.
Study NCT05889468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81Mg Ec Tab
Description: Participant may be provided with a 6-week supply of 81 mg of aspirin prior to discharge from the delivery admission.
Study NCT05889468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participant may be provided with a 6-week supply of placebo to discharge from the delivery admission.
Study NCT05359679 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Value Champion Training Program
Description: Clinicians from primary care clinic sites randomized to the intervention arm of the study will complete a 6-month clinician value champion training program by participating in a series of 12 web-based training sessions. No intervention will be conducted at clinics in the control arm.
Study NCT05359679 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention
Description: Usual clinical care - no value champion present at this clinical setting
Study NCT04767295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab, Albumin Paclitaxel, Carboplatin
Description: Intravenous administration of Camrelizumab (200mg/3weeks); Intravenous administration of albumin paclitaxel (260 mg/m2/3weeks); Intravenous administration of carboplatin (AUC 4/3weeks)
Study NCT04460040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: The first phase of the study will comprise two weeks of control phase when participants will not engage in any exercise training but will be monitored for total daily energy expenditure and its components (REE, SMR, and DIT) and assessed volume of metabolic organs and skeletal muscle efficiency.~Next, participants will start the active phase. In the first two weeks, participants will perform 150 - 200 min/week of a moderate intensity exercise so that they can adapt to the new regime and avoid injury. All exercise training will be monitored using heart rate sensor (HR) to track exercise adherence and HR range goals. Changes in daily non-exercise physical activity and sedentary behavior will be assessed for 10 days pre- and post-intervention by a tri-axial accelerometer. All study participants will be instructed to consume their habitual diet and to maintain the same caloric intake.
Study NCT05469841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systemic pain assessment
Description: Pain will be evaluated via i) pupillometry with 3 successive measurements ii) Behaviour Pain Scale (BPS) and Critical Care Pain Observation Tool (CPOT) score evaluated by an investigator (physician) iii) evolution of physiological parameters (ie heart rate, blood pressure, respiratory rate) iv) Nociception Level Index (NOL) index.
Study NCT06016257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of VirtuaCare™ for home program
Description: Use of VirtuaCare™ system for the Home Program.
Study NCT06011980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Inhibitor
Description: growth inhibitors for 250-500μg/h, ivgtt. for 5 days
Study NCT05546710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: miraDry treatment
Description: The miraDry device is non-invasive and uses microwave energy, focused at the dermal/hypodermal interface, to thermally impact the sweat glands. The treatment area is identified (hair bearing area of the axilla) and high-volume anesthesia is delivered. The miraDry template is selected based upon the size of the treatment area and temporarily applied to the patient's skin. A new miraDry bioTip is attached to the miraDry Handpiece for each treatment session. The Handpiece is then placed on the surface of the skin in the area to be treated. The treatment cycle is activated by a button on the Handpiece. Multiple placements of the Handpiece are required to treat a full axilla in one treatment session.
Study NCT04797455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT-Based Parenting Intervention
Description: The intervention will consist of 4 individual telehealth parent sessions, to be completed within one month after the teen discharges from the inpatient hospital or within one month of linkage to care whatever comes first . Sessions will be 60-90 minute in length and will be offered weekly. Therapists may see parents more than once a week if needed, as long as the total number of sessions does not exceed 4.
Study NCT04797455 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: No parenting intervention provided beyond standard practices on the adolescent psychiatric inpatient unit.
Study NCT04797455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: No parenting intervention provided beyond standard practices on the adolescent psychiatric inpatient unit.
Study NCT05005273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT05005273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days